Ovid Therapeutics (OVID) Competitors $0.31 -0.04 (-10.89%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$0.35 +0.04 (+12.86%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID vs. MCRB, MGNX, VIRI, FTLF, VXRT, EDIT, ELUT, RENB, TLSA, and ADVMShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Seres Therapeutics (MCRB), MacroGenics (MGNX), Virios Therapeutics (VIRI), FitLife Brands (FTLF), Vaxart (VXRT), Editas Medicine (EDIT), Elutia (ELUT), Renovaro (RENB), Tiziana Life Sciences (TLSA), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. Seres Therapeutics MacroGenics Virios Therapeutics FitLife Brands Vaxart Editas Medicine Elutia Renovaro Tiziana Life Sciences Adverum Biotechnologies Seres Therapeutics (NASDAQ:MCRB) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Which has better earnings and valuation, MCRB or OVID? Ovid Therapeutics has lower revenue, but higher earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.33M0.97-$113.72M-$0.23-3.04Ovid Therapeutics$566K39.17-$52.34M-$0.38-0.82 Is MCRB or OVID more profitable? Seres Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Seres Therapeutics' return on equity of 0.00% beat Ovid Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A N/A -55.08% Ovid Therapeutics -5,142.56%-39.24%-26.19% Does the MarketBeat Community prefer MCRB or OVID? Seres Therapeutics received 174 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. Likewise, 71.47% of users gave Seres Therapeutics an outperform vote while only 70.97% of users gave Ovid Therapeutics an outperform vote. CompanyUnderperformOutperformSeres TherapeuticsOutperform Votes53171.47% Underperform Votes21228.53% Ovid TherapeuticsOutperform Votes35770.97% Underperform Votes14629.03% Does the media refer more to MCRB or OVID? In the previous week, Ovid Therapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 9 mentions for Ovid Therapeutics and 6 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 1.25 beat Ovid Therapeutics' score of 0.58 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MCRB or OVID? Seres Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 471.35%. Ovid Therapeutics has a consensus target price of $3.03, indicating a potential upside of 872.53%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Seres Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Ovid Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in MCRB or OVID? 59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, MCRB or OVID? Seres Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. SummaryOvid Therapeutics beats Seres Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.17M$6.89B$5.63B$7.79BDividend YieldN/A2.81%5.37%4.04%P/E Ratio-0.667.4223.6118.68Price / Sales39.17207.04373.3989.80Price / CashN/A65.6738.1734.64Price / Book0.256.206.734.12Net Income-$52.34M$142.11M$3.20B$247.10M7 Day Performance-27.50%-7.28%-5.33%-3.82%1 Month Performance-41.15%-10.45%-0.40%-6.61%1 Year Performance-89.91%-12.86%7.89%-1.67% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.4521 of 5 stars$0.31-10.9%$3.03+872.5%-89.8%$22.17M$566,000.00-0.6660High Trading VolumeMCRBSeres Therapeutics3.4934 of 5 stars$0.71+0.3%$4.00+460.9%-9.6%$124.34M$126.33M-3.10330Positive NewsMGNXMacroGenics3.8937 of 5 stars$1.96-1.8%$7.63+289.0%-91.4%$123.02M$148.34M-1.24430VIRIVirios Therapeutics0.3977 of 5 stars$6.33-7.3%$3.00-52.6%+1,077.2%$121.90MN/A-23.445Gap UpFTLFFitLife Brands4.4964 of 5 stars$13.23-1.9%$20.50+55.0%+1.6%$121.85M$62.76M15.6620Earnings ReportShort Interest ↓Analyst RevisionVXRTVaxart2.2168 of 5 stars$0.51-0.7%$4.00+680.3%-68.5%$116.61M$28.70M-1.25120Analyst RevisionEDITEditas Medicine4.1716 of 5 stars$1.39+6.1%$6.83+391.6%-84.4%$115.34M$32.31M-0.54230Analyst RevisionPositive NewsELUTElutia4.0489 of 5 stars$2.81-3.8%$9.00+220.3%-19.7%$114.47M$24.38M-1.08180Short Interest ↓Positive NewsRENBRenovaro1.0532 of 5 stars$0.72+2.6%N/A-79.5%$114.04MN/A-0.7720TLSATiziana Life Sciences0.6491 of 5 stars$1.08-2.7%N/A+137.9%$113.83MN/A0.008Short Interest ↑ADVMAdverum Biotechnologies4.3553 of 5 stars$5.40+5.9%$27.83+415.4%-69.1%$112.33M$1M-0.90190Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies MCRB Alternatives MGNX Alternatives VIRI Alternatives FTLF Alternatives VXRT Alternatives EDIT Alternatives ELUT Alternatives RENB Alternatives TLSA Alternatives ADVM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OVID) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OVID Stock Free OVID Stock Alerts